Business Wire

Enamine Supplies DSI Poised Fragment and Analogue Libraries to Diamond Light Source XChem Facility and SGC Oxford Screening Efforts

Jaa

Diamond Light Source (Diamond) and the Structural Genomic Consortium (SGC) Oxford announced today that Enamine, a chemical company and producer of novel chemical building blocks and screening libraries, will become a key supplier of poised fragment and analogue libraries to its XChem facility. Enamine will offer a new generation of the hit-finding library, Diamond-SGC-iNEXT (DSI) Poised Library to enable fast and productive fragment-based lead discovery (FBLD).

Diamond, in collaboration with the SGC Oxford, set up the XChem facility for fragment screening by X-ray crystallography to ensure public access to efficient FBLD. In addition, to enable fast and productive lead development, the collaboration developed the concept of “poised fragments” (Cox et al., Chemical Science, 2016), which constitutes its frontline screening strategy. FBLD is a common approach in academia and industry for developing new chemical probes and drug starting points (leads) from weak starting evidence, namely fragment hits. The hits must be chemically altered to improve their binding strength to the target protein, along with other properties.

The DSI Poised Library comprises 768 highly soluble fragments. Each compound is accompanied by its own virtual chemical space, which is readily accessible for synthesis and available for purchase through Enamine. Any hit from this library can be developed with follow-up chemistry within a maximum of three weeks using Enamine’s ground-breaking REAL database.

Prof Frank von Delft, Head of the XChem Collaboration and Principal Beamline Scientist at Diamond Light Source, explained: “The XChem facility has already helped over 60 users find thousands of hits across over 80 targets. To address the subsequent challenge, that chemical elaboration is generally expensive and time consuming, we developed and published the poised approach. Poised fragments can be synthesised in one step from commercially available starting materials using robust, high-yielding reactions, so that libraries of analogues can be synthesised quickly and at a low cost. Coupled with high-throughput biophysical methods, such as XChem screening but also NMR or SPR, this should provide a cost-efficient approach to early-stage fragment-based lead design.”

Dr Anthony Bradley, Project Leader on Fragment Development at SGC Oxford, added: “We quickly discovered that to realise the full power of the approach, we urgently needed to address the problem of compound supply. We are thus delighted to work with Enamine for the materialisation of the DSI Poised Library, fully benefiting from Enamine’s extensive stock of building blocks, capabilities and proven industry solutions. This puts both the primary library and follow-up analogue series within budgets and timelines of even exploratory compound discovery efforts worldwide. The SGC Oxford will be making extensive use of this offering in its many ongoing and future compound development projects.”

Michael Bossert, Head of Strategic Alliances at Enamine, commented: “The high technological degree of specialisation of Diamond and its unique XChem facility, was key to this collaboration. It is important to collaborate with high-tech companies in order to launch high-value technology-based products that aim to improve our customers R&D efficiencies and discovery project successes.”

Prof Paul Brennan, Principal Investigator for Medicinal Chemistry at SGC Oxford, and senior author of the original publication, added: “It is incredibly gratifying to see our original Diamond-SGC Poised Library (DSPL) and poised approach become a commercial offering. We hope this will allow it to become an essential tool in accelerating the development of small molecules probes and drugs.”

The library will be available to a non-exclusive group of nine research institutes operating X-ray and NMR screening located in Europe, USA and China. The European institutes include the partners of the iNEXT fragment screening effort: Diamond, EMBL and ESRF (Grenoble), NKI (Amsterdam), BMRZ (Frankfurt), FMP (Berlin) and CIRMMP (Florence). Other scientists interested in accessing and using the library for their own research are invited to do so.

For further information about the DSI Poised Library: https://xchem.github.io/oxxchem/DSI_poised_fragment_library.xlsx

ENDS

For high-resolution images, please contact lorna.cuddon@zymecommunications.com

Contact information

Zyme Communications
Lorna Cuddon
E: lorna.cuddon@zymecommunications.com
T: +44 7811996942

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Alibaba Cloud Expands European Presence With UK Data Centres22.10.2018 11:00Tiedote

Alibaba Cloud, the cloud computing arm of Alibaba Group, has today announced the opening of two availability zones in the UK, in addition to its Frankfurt and Dubai data centres launched in 2016. This expansion not only extends Alibaba Cloud’s capabilities within Europe, but also serves to highlight the provider’s ongoing commitment to the region. Alibaba Cloud’s local footprint is steadily increasing, with data centres across three EMEA locations: Frankfurt, Dubai, and now London. Answering an increase in demand for Alibaba Cloud services across the EMEA region, the pair of high performance availability zones will enable organisations in the region to accelerate the upgrade of their digital infrastructure enabling more efficient digital transformation initiatives. Business continuity is also a clear focus, with dual availability zones offering stronger disaster recovery capabilities. The London location also boasts 24/7 on-site support – including both security and engineering – as we

New Three-Year Data for Janssen’s TREMFYA®▼ (Guselkumab) Demonstrates Well Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis22.10.2018 11:00Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical study. The data demonstrate well maintained rates of skin clearance with TREMFYA®▼ (guselkumab) treatment at Week 52 (1 year) and Week 156 (3 years) among adult patients with moderate to severe plaque psoriasis.1 The findings, presented at the 37th Fall Clinical Dermatology Conference in Las Vegas, USA, showed nearly 83 percent of patients receiving guselkumab in the Phase 3 VOYAGE 1 study maintained at least a 90 percent improvement in the Psoriasis Area Severity Index (PASI 90), or near complete skin clearance, and an Investigator’s Global Assessment (IGA) score of cleared (0) or minimal disease (1) at Week 156.1 “These findings are impressive as they demonstrate consistency in high rates of skin clearance with guselkumab treatment at Weeks 48, 100 and 156, with every eight-week maintenance therapy,” said Andrew Blauvelt, MD, MBA, President,

Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma22.10.2018 10:51Tiedote

EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal cell carcinoma (aRCC), anticipated to be published at the end of this year.1 The outline of the new proposed guidelines was presented on 19th October at the annual ESMO 2018 Congress in Munich, Germany, and indicated that tivozanib will be included as a first-line treatment recommendation for aRCC clear cell histology patients. The update will position tivozanib as a treatment standard for good (or favourable) risk patients with a Class IIa recommendation, and a treatment option for intermediate risk patients with a Class IIb recommendation.1 The indication of inclusion of tivozanib in the ESMO guidelines follows the grant of a European Commission (EC) licence in August 2017 for this oral, once-daily,a potent selective vascular endothelial growth factor receptor tyrosine kinase inhibitors (

Open Fiber Powers Its Optical Network With SM Optics WDM ROADM22.10.2018 10:00Tiedote

Open Fiber a national wholesales operator awards SM Optics, part of SIAE MICROELETTRONICA group a contract to supply and deploy WSS-free WDM ROADM technology extending fibre connectivity from their fibre backbone to metro/regional sites. The new network transports the FTTH (fibre-to-the-home) and FWA (Fixed-wireless-access) aggregated traffic, delivering ultra-broadband service to houses and local businesses. Open Fiber mission is to build a nationwide fiber network, bringing fibre connectivity to the vast majority of households and enterprises in the country, with a target of almost 19 million property units. This optical access infrastructure will enable operators delivering next generation services from FTTH broadband network for data, gaming, video streaming and mobile connectivity to 5G and IoT. SM Optics optical transport solution offers unprecedented flexibility in the smallest footprint, successfully meeting the challenge of limited space deployment and low power consumption. F

Zscaler Extends Cloud DLP Service with Inline Exact Data Match for Massive Data Sets Covering Users Globally22.10.2018 09:30Tiedote

Zenith Live Europe – Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced inline Exact Data Match (EDM) with native SSL inspection as part of its advanced Cloud Data Loss Prevention (DLP) service. The inline EDM capability extends the Zscaler™ cloud platform to protect against the loss of sensitive information across all users and branches with more precision while reducing the number of false positives to near zero. This service is provided in the Zscaler cloud, providing the capacity of one billion data points per customer across 100 data centers globally. Traditional DLP appliances that sit in the data center are expensive and resource-intensive, and their protection can be subpar, often failing to alert an organization until after data has been compromised. Zscaler’s inline EDM with native SSL inspection blocks sensitive information before it leaves the network. In the first half of 2018, the Zscaler cloud platform blocked an average of 800,000 SSL-encrypted tr

Vivior Chairman Receives Award for Outstanding Contributions to Refractive Surgery22.10.2018 09:00Tiedote

Michael Mrochen, PhD, Chairman of the Board of Directors at Vivior, receives the Casebeer Award from the International Society of Refractive Surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181021005012/en/ Michael Mrochen, PhD Chairman of the Board of Directors Vivior AG (Photo: Business Wire) The International Society of Refractive Surgery (ISRS), a partner of the American Academy of Ophthalmology, is the leading worldwide organization for refractive surgeons. Each year, ISRS awards members for their special contributions to the ISRS, as well as their dedication to the field. The Casebeer Award recognizes an individual for his or her outstanding contributions to refractive surgery through nontraditional research and development activities (https://www.isrs.org/about-isrs/awards). Michael Mrochen is internationally known for his pioneering work on corneal laser surgery, corneal cross linking, ocular biometry and corn

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme